Clinical Trials Sponsored by Christoph Nissen

Total 1209 results

Ipsen

Terminated

IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population (EDISON)

IGF-1 Deficiency

Spain
Ipsen

Completed

The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)

Insomnia

Russian Federation
Ipsen

Completed

Non Interventional Post Marketing Programme in Neuroendocrine Tumours

Neuroendocrine Tumors

United Kingdom
Ipsen

Terminated

Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg (ACRO-OPTIM)

Acromegaly

France
Ipsen

Completed

A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months (DIE-NIS)

Deep Infiltrating Endometriosis (DIE)

China
Ipsen

Completed

Validation Study of the SAGIT® Instrument in Acromegaly (SAGIT)

Acromegaly

United States, United Kingdom, Italy, Netherlands, France, Belgium, Brazil, Denmark, Germany, Spain
Ipsen

Not yet recruiting

Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma (CabOSTar)

Osteosarcoma | Osteosarcoma in Children | Osteosarcoma in Adolescents and Young Adults
Ipsen

Recruiting

Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation

Pregnancy Related

United States
Ipsen

Recruiting

A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly (BackSOM)

Acromegaly | Gastro-enteropancreatic Neuroendocrine Tumor

United States
Ipsen

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

Primary Biliary Cholangitis (PBC)

United States, Spain, France, Korea, Republic of, Italy, Czechia, Poland, Romania
Ipsen

Recruiting

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (ELMWOOD)

Primary Sclerosing Cholangitis

United States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
Ipsen

Recruiting

Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment (ROSE)

Early-stage Breast Cancer

Italy
Ipsen

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines (LANTIC)

Moderate to Severe Upper Facial Lines

Germany, France
Ipsen

Recruiting

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. (CABOCARE)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

Germany, Austria
Ipsen

Terminated

A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET

Neuroendocrine Tumors

Australia
Ipsen

Completed

Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone. (EQUINOXE)

Prostate Cancer

France
Ipsen

Completed

A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)

Muscle Spasticity | Spastic Hemiparesis

United States
Ipsen

Terminated

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

Insulin-like Growth Factor-1 Deficiency

United States
Ipsen

Completed

A Single Centre, Prospective, Observational Study to Assess the Use of the Rehabilitation Tool, GripAble, in Patients With Upper Limb Spasticity Receiving Botulinum Toxin-A (BoNT-A) in the United Kingdom (UK).

Upper Limb Spasticity (ULS)

United Kingdom
Ipsen

Completed

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs (PALACE)

Gastroenteropancreatic Neuroendocrine Tumor

China
Ipsen

Completed

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

Central Precocious Puberty

China
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Ipsen

Completed

Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Cervical Dystonia

United States, Russian Federation
Ipsen

Completed

Dysport® Adult Lower Limb Spasticity Study

Leg Spasticity

United States, Australia, France, Belgium, Czechia, Hungary, Italy, Poland, Portugal, Russian Federation, Slovakia
Ipsen

Completed

Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children (PUL)

Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children

United States, Poland, Spain, Belgium, Israel, Turkey, Czechia, Mexico
Ipsen

Completed

Dysport® Adult Lower Limb Spasticity Follow-on Study

Post-stroke Spasticity | Spasticity Post-Traumatic Brain Injury

United States, Australia, France, Belgium, Hungary, Poland, Portugal, Slovakia, Czechia, Russian Federation, Italy
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 (CONTENT1)

Overactive Bladder | Urinary Incontinence

United States, Korea, Republic of, Czechia, Netherlands, Romania, Poland, Turkey, Portugal, Canada, Italy
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (CONTENT2)

Overactive Bladder | Urinary Incontinence

Spain, Israel, Russian Federation, France, Germany, Australia, Belgium, Brazil, United Kingdom, Mexico, Colombia, Chile, Argentina, Lithuania, Peru, Ukraine
Ipsen

Completed

Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia

Cervical Dystonia

France, Belgium, Czechia, Australia, Poland, Portugal, Ukraine, Hungary, Russian Federation, Austria, Germany
Ipsen

Completed

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Acromegaly

Germany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
Ipsen

Completed

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma (CASSIOPE)

Renal Cell Carcinoma

Germany, Spain, Italy, Greece, Belgium, France, Netherlands, United Kingdom, Austria, Czechia, Poland
Ipsen

Completed

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (PREF-NET)

Neuroendocrine Tumours (NET)

United Kingdom
Ipsen

Completed

Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinA (RETURN)

Spasticity

Brazil
Ipsen

Terminated

Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (PanNET)

Pancreatic Neuroendocrine Tumor

Spain, Portugal
Ipsen

Completed

Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy (EASYKID)

Digestive System Disease

Czechia, France, Germany, Poland, Netherlands, Italy
Ipsen

Completed

Dysport in Post-Surgical Neuralgia (PMOD03)

Chronic Scar Pain

United Kingdom
Ipsen

Completed

Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

Lower Limb Spasticity

United States
Ipsen

Terminated

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

Primary Insulin-like Growth Factor-1 Deficiency

United States
Ipsen

Completed

To Document the Effectiveness of BoNT-A Injection in Adult Subjects With Upper Limb Spasticity Following Stroke (ULIS2)

Muscle Spasticity

Australia, Austria, Belgium, China, Czechia, Denmark, Finland, France, Germany, Italy, Korea, Republic of, Malaysia, Mexico, Philippines, Portugal, Russian Federation, Singapore, Spain, Sweden, Taiwan, Thailand, United Kingdom
Ipsen

Completed

Phase IV-Cervical Dystonia-INTEREST IN CD2 (INTEREST_INCD2)

Cervical Dystonia

Korea, Republic of, Thailand, Belgium, Israel, Taiwan, Germany, Hungary, United States, Singapore, Slovenia, United Kingdom, Australia, Malaysia, Serbia, Estonia, Turkey, Italy, Poland, China, Sweden, Portugal, Algeria, Austria, Brazil, Czechi... and more
Ipsen

Completed

Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults (ADIASE)

Acute Diarrhoea

Egypt, Algeria, Czechia, Lebanon, Poland, Tunisia
Ipsen

Completed

A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK

Advanced Renal Cell Carcinoma

United Kingdom
Ipsen

Completed

Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours (QUALINETS)

Gastrointestinal Neuroendocrine Tumours

Spain, Portugal
Ipsen

Terminated

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Breast Cancer

Austria
Ipsen

Completed

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

Growth Disorders | Insulin-Like Growth Factor-1 Deficiency

United States
Ipsen

Completed

Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours (STREET)

Gastroenteropancreatic Neuroendocrine Tumours

Sweden
Ipsen

Withdrawn

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly (PLAN-A)

Acromegaly
Ipsen

Completed

Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer
Ipsen

Completed

To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.

Chronic Constipation

Thailand
Ipsen

Completed

Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis

Migraine

Czechia, Poland, Slovakia

3

Subscribe